Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 12/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955417 | 0.93 | GCK (0.44) | GCKIDO1 | |
| SCHEMBL958722 | 0.92 | GCK (0.45) | GCK | |
| SCHEMBL955209 | 0.89 | GCK (0.47) | GCKSCN4A | |
| SCHEMBL956376 | 0.89 | GCK (0.44) | GCKNPC1RAB9AIDO1 | |
| SCHEMBL957680 | 0.88 | GCK (0.46) | GCKNPC1RAB9A | |
| SCHEMBL955972 | 0.86 | NOTUM (0.48) | GCKNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL958752 | 0.86 | GCK (0.46) | GCKBRD4KMT2A | |
| SCHEMBL955080 | 0.86 | GCK (0.46) | GCKNPC1RAB9ASMN1; SMN2IDO1 | |
| SCHEMBL955304 | 0.85 | GCK (0.45) | GCKNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL955909 | 0.85 | GCK (0.45) | GCKNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456767-B1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | claimed |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HAYNES NANCY-ELLEN | 2011-01-27 | — | — | US | claimed |
| EP-2456767-B1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HAYNES NANCY-ELLEN | 2011-01-27 | — | — | US | disclosed |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HAYNES NANCY-ELLEN | 2011-01-27 | — | — | US | disclosed |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HAYNES NANCY-ELLEN | 2011-01-27 | — | — | US | disclosed |
| WO-2011009845-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011009845-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | GCK 1/4885CREBBP 1179/4885BRD4 2857/4885 |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | GCK 1/4885CREBBP 1179/4885BRD4 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.